Cargando…

Comparative efficacy and safety of immunotherapy for patients with advanced or metastatic esophageal squamous cell carcinoma: a systematic review and network Meta-analysis

BACKGROUND: The study aimed to compare efficacy and safety of various immune checkpoint inhibitors for patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC). METHODS: We searched Medline, Web of Science, Cochrane Central Register of Controlled Trials, Embase, Clinical Trials...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gao, Tian-Tian, Shan, Jia-Hui, Yang, Yu-Xian, Zhang, Ze-Wei, Liu, Shi-Liang, Xi, Mian, Liu, Meng-Zhong, Zhao, Lei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9482734/ https://www.ncbi.nlm.nih.gov/pubmed/36115960 http://dx.doi.org/10.1186/s12885-022-10086-5

Ejemplares similares

Recent Advances in Combination of Immunotherapy and Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
por: Wang, Ruixi, et al.
Publicado: (2022)

Efficacy and safety of neoadjuvant chemotherapy and immunotherapy in locally resectable advanced esophageal squamous cell carcinoma
por: Wu, Zhigang, et al.
Publicado: (2021)

Efficacy and prognostic analysis of chemoradiotherapy in patients with thoracic esophageal squamous carcinoma with cervical lymph nodal metastasis alone
por: Zhang, Peng, et al.
Publicado: (2014)

Progression‐free survival at 3 years is a reliable surrogate for 5‐year overall survival for patients suffering from locally advanced esophageal squamous cell carcinoma
por: Yang, Yu‐Xian, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Camrelizumab Immunotherapy versus Docetaxel or Irinotecan Chemotherapy as Second-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma
por: Lin, Ying-Tao, et al.
Publicado: (2021)

Immunotherapy with or without radiotherapy for metastatic or recurrent esophageal squamous cell carcinoma: A real-world study
por: Wu, Xiaoyue, et al.
Publicado: (2022)

Efficacy and safety of combined treatment with pembrolizumab in patients with locally advanced or metastatic esophageal squamous cell carcinoma in the real world
por: Zhang, Pei, et al.
Publicado: (2022)

The Safety and Efficacy of Apatinib Treatment in Addition to Concurrent Chemoradiotherapy in Patients with Nonoperative Locally Advanced Esophageal Squamous Cell Carcinoma
por: Hu, Lijun, et al.
Publicado: (2020)

Efficacy and safety of apatinib treatment for advanced esophageal squamous cell carcinoma
por: Li, Jianqiang, et al.
Publicado: (2017)

The efficacy and safety of neoadjuvant immunotherapy in resectable locally advanced esophageal squamous cell carcinoma: A systematic review and meta-analysis
por: He, Wenwu, et al.
Publicado: (2023)

Efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy in locally advanced esophageal cancer: A meta-analysis
por: Wang, Jincheng, et al.
Publicado: (2022)

Is There a Benefit in Receiving Concurrent Chemoradiotherapy for Elderly Patients with Inoperable Thoracic Esophageal Squamous Cell Carcinoma?
por: Zhang, Peng, et al.
Publicado: (2014)

Chemoimmunotherapy in advanced esophageal squamous cell carcinoma: optimizing chemotherapy regimens for immunotherapy combinations
por: Liu, Zhichao, et al.
Publicado: (2022)

Clinical efficacy and safety of apatinib combined with S-1 in advanced esophageal squamous cell carcinoma
por: Zhao, Jian, et al.
Publicado: (2019)

Insulin-like growth factor binding protein-3 is a new predictor of radiosensitivity on esophageal squamous cell carcinoma
por: Luo, Li-Ling, et al.
Publicado: (2015)

The efficacy and safety of sintilimab combined with chemotherapy as the first-line treatment for metastatic esophageal squamous cell carcinoma
por: Zhao, Zheng, et al.
Publicado: (2023)

Cost-Effectiveness of Nivolumab Immunotherapy vs. Paclitaxel or Docetaxel Chemotherapy as Second-Line Therapy in Advanced Esophageal Squamous Cell Carcinoma in China
por: Lin, Ying-tao, et al.
Publicado: (2022)

Comparative Outcomes of Induction Chemotherapy Followed By Definitive Chemoradiotherapy versus Chemoradiotherapy Alone In Esophageal Squamous Cell Carcinoma
por: Luo, Li-Ling, et al.
Publicado: (2017)

Efficacy and Safety of Immune Checkpoint Inhibitor in Advanced Esophageal Squamous Cell Carcinoma: A Meta-Analysis
por: Gu, Yi-Min, et al.
Publicado: (2021)

The Modified Glasgow Prognostic Score Is an Independent Prognostic Factor in Patients with Inoperable Thoracic Esophageal Squamous Cell Carcinoma Undergoing Chemoradiotherapy
por: Zhang, Peng, et al.
Publicado: (2014)

Immunotherapy for Esophageal Squamous Cell Carcinoma
por: Kojima, Takashi, et al.
Publicado: (2017)

Safety and Feasibility of Radiotherapy Plus Camrelizumab for Locally Advanced Esophageal Squamous Cell Carcinoma
por: Zhang, Wencheng, et al.
Publicado: (2021)

Pre-immunotherapy radiotherapy enhanced the efficacy of multi-line sintilimab in unresectable advanced esophageal squamous cell carcinoma
por: Xu, Shuhui, et al.
Publicado: (2023)

Immunotherapy Advances in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Its Relationship With Human Papillomavirus
por: Wang, Huanhuan, et al.
Publicado: (2021)

Perioperative Outcomes of Minimally Invasive Esophagectomy After Neoadjuvant Immunotherapy for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
por: Cheng, Jiahan, et al.
Publicado: (2022)

The efficacy and safety of simultaneous integrated dose reduction in clinical target volume with intensity-modulated radiotherapy for patients with locally advanced esophageal squamous cell carcinoma
por: Zhao, Jingjing, et al.
Publicado: (2020)

Perioperative immunotherapy for esophageal squamous cell carcinoma: Now and future
por: Liu, Yong
Publicado: (2023)

Efficacy and safety of immunochemotherapy, immunotherapy, chemotherapy, and targeted therapy as first-line treatment for advanced and metastatic esophageal cancer: a systematic review and network meta-analysis
por: Gao, Zhen, et al.
Publicado: (2023)

Association of insulin-like growth factor-binding protein-3 with radiotherapy response and prognosis of esophageal squamous cell carcinoma
por: Luo, Li-Ling, et al.
Publicado: (2015)

Immunotherapy for Squamous Esophageal Cancer: A Review
por: Petrillo, Angelica, et al.
Publicado: (2022)

Efficacy and safety of anti-PD-1 antibody plus chemoradiotherapy in locally advanced esophageal squamous cancer
por: Ma, Ji, et al.
Publicado: (2023)

Safety and efficacy of anti-EGFR monoclonal antibody (SCT200) as second-line therapy in advanced esophageal squamous cell carcinoma
por: Bai, Ming, et al.
Publicado: (2022)

Safety and Feasibility of Esophagectomy Following Neoadjuvant Immunotherapy Combined with Chemotherapy for Esophageal Squamous Cell Carcinoma
por: Gu, Yi-Min, et al.
Publicado: (2022)

Comparison of neoadjuvant immunotherapy plus chemotherapy versus chemotherapy alone for patients with locally advanced esophageal squamous cell carcinoma: A propensity score matching
por: Jing, Shao-Wu, et al.
Publicado: (2022)

The Predictive Value of Systemic Inflammatory Factors in Advanced, Metastatic Esophageal Squamous Cell Carcinoma Patients Treated with Camrelizumab
por: Liu, Jiang, et al.
Publicado: (2022)

Safety and efficacy of radiation and chemoradiation in patients over 70 years old with inoperable esophageal squamous cell carcinoma
por: XU, HONG-YU, et al.
Publicado: (2014)

Nimotuzumab promotes radiosensitivity of EGFR-overexpression esophageal squamous cell carcinoma cells by upregulating IGFBP-3
por: Zhao, Lei, et al.
Publicado: (2012)

Trafficking protein TMED3 promotes esophageal squamous cell carcinoma
por: Yang, Yuxian, et al.
Publicado: (2023)

Unilateral Cervical Nodal Metastasis Is an Independent Prognostic Factor for Esophageal Squamous Cell Carcinoma Patients Undergoing Chemoradiotherapy: A Retrospective Study
por: Zhang, Peng, et al.
Publicado: (2014)

Prognostic Value of Lactate Dehydrogenase in Second-Line Immunotherapy for Advanced Esophageal Squamous Cell Carcinoma
por: Li, Yan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_j6sbo7fr8ddo392a69el4rtato